In a phase 3 trial, tenapanor, which reduces paracellular phosphate transport in the intestine, lowered elevated serum phosphorus in patients on hemodialysis.
In a new study, patients with serum phosphate levels above 1.78 mmol/L at the start of peritoneal dialysis had a nearly 2-fold increased risk of death.
In a 2-phased trial, hyperphosphatemia and is sequelae developed in a smaller proportion of patients taking activated charcoal compared with placebo recipients.
Study supports the hypothesis that altered tubular phosphate handling drives the increase in serum phosphate during SGLT2 inhibition.
In 2 studies, roughly a third of hemodialysis patients achieved within-range serum phosphate levels after converting to sucroferric oxyhydroxide from another phosphate binder.
In a small study of hemodialysis patients, substituting egg white for meat and fish in 3 meals per week resulted in a significant decrease in serum phosphate.
In a small study of patients on maintenance hemodialysis, phosphate binder use did not affect appetite, food intake, or malnutrition-inflammation score.
In a Japanese study, patients with the lowest serum phosphate levels at dialysis initiation had the greatest death risk.
Trial results do not support use of vitamin D receptor activators to prevent cardiovascular events in patients with end-stage renal disease and low intact parathyroid hormone levels.
Analyses demonstrated that an ABI of 1.79 correlated with radiographic evidence of calcified vessels.